<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Health Serv Res</journal-id><journal-title>BMC Health Services Research</journal-title><issn pub-type="epub">1472-6963</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16756680</article-id><article-id pub-id-type="pmc">1543623</article-id><article-id pub-id-type="publisher-id">1472-6963-6-68</article-id><article-id pub-id-type="doi">10.1186/1472-6963-6-68</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Hoch</surname><given-names>Jeffrey S</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jeffrey.hoch@utoronto.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Rockx</surname><given-names>Marie Antoinette</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>mrockx@uwo.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Krahn</surname><given-names>Andrew D</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>akrahn@uwo.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, Canada</aff><aff id="I2"><label>2</label>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada</aff><aff id="I3"><label>3</label>Department of Medicine, University of Western Ontario, London Ontario, Canada</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>6</day><month>6</month><year>2006</year></pub-date><volume>6</volume><fpage>68</fpage><lpage>68</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6963/6/68"/><history><date date-type="received"><day>18</day><month>2</month><year>2006</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Hoch et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Hoch et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Hoch
               S
               Jeffrey
               
               
               jeffrey.hoch@utoronto.ca
            </dc:author><dc:title>
            Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope
         </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Health Services Research 6(1): 68-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1472-6963(2006)6:1&#x0003c;68&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1472-6963</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Cost-effectiveness acceptability curves (CEACs) describe the probability that a new treatment or intervention is cost-effective. The net benefit regression framework (NBRF) allows cost-effectiveness analysis to be done in a simple regression framework. The objective of the paper is to illustrate how net benefit regression can be used to construct a CEAC.</p></sec><sec sec-type="methods"><title>Methods</title><p>One hundred patients referred for ambulatory monitoring with syncope or presyncope were randomized to a one-month external loop recorder (n = 49) or 48-hour Holter monitor (n = 51). The primary endpoint was symptom-rhythm correlation during monitoring. Direct costs were calculated based on the 2003 Ontario Health Insurance Plan (OHIP) fee schedule combined with hospital case costing of labour, materials, service and overhead costs for diagnostic testing and related equipment.</p></sec><sec><title>Results</title><p>In the loop recorder group, 63.27% of patients (31/49) had symptom recurrence and successful activation, compared to 23.53% in the Holter group (12/51). The cost in US dollars for loop recording was $648.50 and $212.92 for Holter monitoring. The incremental cost-effectiveness ratio (ICER) of the loop recorder was $1,096 per extra successful diagnosis. The probability that the loop recorder was cost-effective compared to the Holter monitor was estimated using net benefit regression and plotted on a CEAC. In a sensitivity analysis, bootstrapping was used to examine the effect of distributional assumptions.</p></sec><sec><title>Conclusion</title><p>The NBRF is straightforward to use and interpret. The resulting uncertainty surrounding the regression coefficient relates to the CEAC. When the link from the regression's p-value to the probability of cost-effectiveness is tentative, bootstrapping may be used.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Out patient ambulatory monitoring is often performed in patients with syncope (e.g., fainting or passing out) that present in the primary care setting to diagnose or exclude an arrhythmia, a potentially serious etiology [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. This short-term monitoring device may take the form of an external loop recorder or a Holter monitor. The purpose of monitoring is to obtain a symptom-rhythm correlation during the monitored period (i.e., to have the monitoring device actively record a patient experiencing symptoms). Several studies have reported the diagnostic yield of the two monitoring modalities, suggesting a higher yield from the longer duration of monitoring provided by a loop recorder [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. One recent randomized trial confirmed the higher diagnostic yield [<xref ref-type="bibr" rid="B5">5</xref>]. There is a lack of data about the cost of investigation of syncope presenting in the community. Referred and hospitalized patients are known to generate costs estimated between $3,000 and $25,000 dollars [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. After a primary diagnostic trial [<xref ref-type="bibr" rid="B5">5</xref>], we sought to establish the cost of investigation of "community-acquired" syncope and to evaluate the cost-effectiveness of the two monitoring strategies in a prospective randomized trial [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>A new health care treatment, intervention or technology is cost-effective if (1) the extra cost of (2) an extra unit of effect is less than (3) the decision maker's willingness to pay for it. A cost-effectiveness analysis (CEA) can report (1) and (2), representing two of the three pieces of information necessary to determine cost-effectiveness. Specifically, an incremental cost-effectiveness ratio (ICER) is the ratio of extra cost to extra effect (i.e., &#x00394;C/&#x00394;E). Thus, a CEA generates an estimate of the extra cost for an additional unit of effect, but the merit of the trade-off is typically a matter of opinion. In other words, the data are generally silent on whether the extra effect is worth the extra cost. For example, a new drug for multiple sclerosis may provide an extra quality adjusted life year (QALY) for &#x000a3;35,000. The new drug is cost-effective if the decision maker is willing to pay &#x000a3;35,000 or more for an extra QALY. Thus the verdict of cost-effectiveness depends upon the decision maker's willingness to pay (&#x003bb;), a value not known from the cost and effect data. There is additional uncertainty beyond the fact that &#x003bb; is unknown. The uncertainty comes from the fact that the sample ICER is a statistical estimate. For example, if the <italic>true </italic>ICER is &#x000a3;30,000 per QALY, the ICER <italic>estimate </italic>could be more or less due to sampling variability. In fact, the multiple sclerosis drug with the ICER estimate of &#x000a3;35,000 per QALY could have a true ICER of &#x000a3;30,000 per QALY. It would be a mistake to conclude there is no chance that the drug is cost-effective if &#x003bb; = &#x000a3;31,000, for example.</p><p>The cost-effectiveness acceptability curve (CEAC) elegantly handles both uncertainty problems. This paper, building on recent work by Fenwick and colleagues [<xref ref-type="bibr" rid="B21">21</xref>], illustrates how to use the net benefit regression framework (NBRF) [<xref ref-type="bibr" rid="B22">22</xref>] to construct a CEAC. After a brief summary of relevant statistical concepts, this paper uses clinical trial data from a recently published CEA comparing external loop recorders with Holter monitors for ambulatory monitoring of syncope.</p></sec><sec sec-type="methods"><title>Methods</title><p>One hundred patients referred for ambulatory monitoring with syncope or presyncope (hereafter described as syncope) were randomized to a one-month external loop recorder (n = 49) or 48-hour Holter monitor (n = 51). Patients provided written informed consent, and the protocol was approved by the University of Western Ontario Ethics Review Board. The primary endpoint was symptom-rhythm correlation during monitoring. Direct costs in Canadian dollars were calculated from the Ministry of Health's perspective based on the 2003 Ontario Health Insurance Plan (OHIP) fee schedule for professional fees and on hospital case costing data for the calculation of labour, materials, service and overhead for diagnostic testing and related equipment. Costs were converted to US Dollars using a conversion rate converted on July 20th, 2005 of ($1 USD = $1.21543 CAD) [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Loop recorders were both more costly and more effective than Holter monitors. For the loop recorder, the cost in US dollars was $648.50 and for the Holter monitor $212.92 [<xref ref-type="bibr" rid="B20">20</xref>]. The extra cost of $435.58 for the loop recorder was accompanied by a 39.74% increase of success while monitoring (in the loop recorder group 31 of 49 or 63.27% of patients had symptom recurrence and successful activation, compared to 12 of 51 or 23.53% in the Holter group). The ICER estimate was $1096 per additional diagnosis. The CEAC finds purchase here as there is uncertainty about the maximum a decision maker would pay for an additional diagnosis coupled with the statistical variability inherent in trial data. As an alternative to the method illustrated by Fenwick and colleagues [<xref ref-type="bibr" rid="B21">21</xref>], we use the NBRF to show how to construct the CEAC.</p><p>The CEAC has been advocated for summarizing the results of a CEA because it highlights the relationship between the assessment of cost-effectiveness and the unknown &#x003bb; [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. As originally described, the CEAC originates from a Bayesian context; however, the CEAC can be given a frequentist interpretation. For a given &#x003bb;, the CEAC is equal to one minus the <italic>one-sided </italic>significance level for testing the null hypothesis that the "new treatment" is not cost-effective (i.e., the additional benefits are outweighed by the additional costs) [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Under this frequentist framework, the CEAC can be viewed as illustrating a decision rule for rejecting the null hypothesis that the intervention is not cost-effective.</p><p>Alternatively, the CEAC can be interpreted in a 'Bayesian' fashion [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>] as: the probability that an individual, with a set of prior beliefs about the cost-effectiveness of the new treatment, now believes the new treatment to be cost-effective (i.e., the additional benefits outweigh the additional costs). While a Bayesian approach provides a well-justified interpretation for a CEAC, it presents other dilemmas. For example, there exist many 'Bayesian' CEACs &#x02013; namely one for every set of prior beliefs &#x02013; with no criteria for choosing between them. This is important because every CEAC is 'correct' for its given prior. Thus, the calculation of <italic>a </italic>Bayesian CEAC requires the specification of the prior distribution of the cost-effectiveness data before the data were collected. Typically as a reference case scenario, it is common and convenient to use a 'non-informative' prior which allows the data to overwhelm prior beliefs. However, except in the simplest of examples there is no agreement about the definition of a reference prior distribution and many so-called non-informative priors are not non-informative at all (see section 5.5.1 of [<xref ref-type="bibr" rid="B29">29</xref>]). When using a 'non-informative' prior with the NBRF (in this case assuming there is no reason to modify the results of the data analysis), the Bayesian mechanics work in the background and formal derivation of the posterior distribution can be avoided. In other words, one can run a net benefit regression and use the resulting parts to illustrate the probability that a new treatment or intervention is cost-effective (NB: The p-value itself does not provide an estimate of the probability of cost-effectiveness when there is prior information. This is a fundamental distinction between the interpretation of a p-value and a posterior probability [<xref ref-type="bibr" rid="B30">30</xref>]. For a more comprehensive discussion about the use of genuine prior information in cost-effectiveness analyses readers are referred to [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>]).</p><p>The NBRF was introduced to facilitate the use of regression tools in economic evaluation [<xref ref-type="bibr" rid="B22">22</xref>]. Net benefit regression uses as the dependent variable, net benefit <italic>nb</italic><sub><italic>i </italic></sub>= &#x003bb;&#x000b7;<italic>effect</italic><sub><italic>i </italic></sub>- <italic>cost</italic><sub><italic>i </italic></sub>from person-level effect (<italic>effect</italic><sub><italic>i</italic></sub>) and cost (<italic>cost</italic><sub><italic>i</italic></sub>) data (as a matter of preference, the analyst may use net health benefits [<xref ref-type="bibr" rid="B34">34</xref>] instead of net monetary benefits [<xref ref-type="bibr" rid="B35">35</xref>]). When ordinary least squares (OLS) is used to estimate the simple linear regression</p><p><italic>nb</italic><sub><italic>i </italic></sub>= &#x003b2;<sub>0 </sub>+ &#x003b2;<sub>1</sub><italic>TX </italic>+ &#x003b5;</p><p>where <italic>TX </italic>is a "new treatment" indicator variable (e.g., <italic>TX </italic>= 1 if the patient received a loop recorder and <italic>TX </italic>= 0 if the patient received a Holter monitor), the coefficient estimate of &#x003b2;<sub>1</sub>, call this b<sub>1</sub>, equals the difference in mean <italic>nb </italic>for the loop and Holter groups. It can be shown [<xref ref-type="bibr" rid="B22">22</xref>] that when this difference is greater than zero (i.e., when the loop group has greater mean net benefits than the Holter group), then &#x00394;C/&#x00394;E &#x0003c; &#x003bb;. In other words, if b<sub>1 </sub>&#x0003e; 0, then the loop recorder is cost-effective relative to the Holter monitor (or the incremental net benefit is positive). The statistical uncertainty involving the cost and effect data is expressed in the p-value for b<sub>1</sub>. The p-value for b<sub>1 </sub>can be used to make the y-axis of the CEAC [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>]; however, caution must be exercised in two regards.</p><p>Using the NBRF and a Bayesian perspective, the CEAC illustrates the probability that a "new treatment" is cost-effective by graphing the probability that &#x003b2;<sub>1 </sub>&#x0003e; 0 as a function of &#x003bb;. Most statistical packages have regression programs that report a two-sided p-value, but in this case a one-sided probability is indicated. Because the two-sided p-value is twice as much probability as is needed, it is necessary to divide it by two (this converts the two-sided p-value into a one-sided p-value). Figure <xref ref-type="fig" rid="F1">1</xref> illustrates this and the importance of checking the sign of b<sub>1</sub>. When b<sub>1 </sub>&#x0003c; 0, the probability that new treatment is cost-effective equals the one-sided p-value, and when b<sub>1 </sub>&#x0003e; 0, the probability that new treatment is cost-effective equals one minus the one-sided p-value. Thus when using the p-value from a regression to make a CEAC, one must check that one is using the one-sided p-value and that one is doing the correct calculation given the sign of b<sub>1 </sub>(i.e., 1/2 p-value of b<sub>1 </sub>when b<sub>1 </sub>&#x0003c; 0 or 1 - 1/2 p-value of b<sub>1 </sub>when b<sub>1 </sub>&#x0003e; 0). Lastly, because the p-value of a parametric analysis is derived from a distributional assumption, non-parametric methods like bootstrapping may offer better alternatives when distributional concerns arise (e.g., the data do not appear distributed normally or with constant variance).</p></sec><sec><title>Results</title><p>Each study participant who received a loop recorder incurred costs of $648.50 and 31 of the 49 (63.27%) had symptom recurrence and successful activation. In comparison, the Holter monitors cost $212.92 for each study participant and only 12 of the 51 (23.53%) experienced a successful outcome. The NBRF was implemented by estimating with OLS the regression</p><p><italic>nb</italic><sub><italic>i </italic></sub>= &#x003b2;<sub>0 </sub>+ &#x003b2;<sub>1</sub><italic>LOOP </italic>+ &#x003b5;</p><p>where <italic>LOOP </italic>is an indicator variable equaling one if the patient received a loop recorder and zero if the patient received a Holter monitor. Table <xref ref-type="table" rid="T1">1</xref> shows how the net benefit statistic (<italic>nb</italic><sub><italic>i</italic></sub>) was calculated for each person when &#x003bb; was set to $1000.</p><p>Table <xref ref-type="table" rid="T2">2</xref> presents the complete results of five net benefit regressions using &#x003bb; = $500, $1000, $1500, $2000 and $2500. To illustrate how the CEAC can be computed using net benefit regression, Table <xref ref-type="table" rid="T3">3</xref> lists regression estimates of the <italic>LOOP </italic>indicator variable for &#x003bb; = $500 through $3000 (the horizontal axis for the CEAC) as well as the regression and bootstrap estimates of the probability that the loop recorder is cost-effective (the vertical axis for the CEAC). For &#x003bb; &#x0003c; $1000, the estimate of the incremental net benefit is negative (i.e., b<sub>1 </sub>&#x0003c; 0), so the quantity to calculate for the CEAC's vertical axis is simply one half of the two-sided p-value. For &#x003bb; &#x0003e; $1000, the estimate of the incremental net benefit is positive (i.e., b<sub>1 </sub>&#x0003e; 0), so the quantity to calculate for the CEAC's vertical axis is one minus one half of the two-sided p-value. Figure <xref ref-type="fig" rid="F2">2</xref> illustrates the resulting CEAC. Because the p-value is based on distributional assumptions that may not hold with small sample sizes or non-constant variance, bootstrapping can be used as a non-parametric alternative to obtain values for the CEAC's vertical axis. For this example, we drew 1000 bootstrapped samples of n = 100 from our original sample. The resulting estimates of the probability that the incremental net benefit is positive are reported in the last column of Table <xref ref-type="table" rid="T3">3</xref>.</p></sec><sec><title>Discussion</title><p>A CEAC indicates a 50% chance of cost-effectiveness when &#x003bb; equals the sample estimate of the ICER [<xref ref-type="bibr" rid="B26">26</xref>]. The ICER for the loop recorder was $1,096 per extra successful diagnosis. Table <xref ref-type="table" rid="T3">3</xref> shows that when &#x003bb; is within $500 of the ICER estimate, the probability of cost-effectiveness is quite sensitive. For example, at &#x003bb; = $500, the probability that loop recorders are cost-effective is 0%, but at &#x003bb; = $1500 it is approximately 88%. Figure <xref ref-type="fig" rid="F2">2</xref> illustrates this, as the most dramatic gains in the height of the curve (from 0% to 88%) occur between &#x003bb; = $500 and $1500. Alternatively, the curve is mostly flat for &#x003bb; &#x0003c; $ 500 and &#x003bb; &#x0003e; $1500. While we may never know the real value of &#x003bb;, if it is assumed to be near the low range of the costs generated by referred and hospitalized patients (e.g., $3000 dollars), there appears to be a good chance that loop recorders are cost-effective.</p><p>As reflected in the last two columns of Table <xref ref-type="table" rid="T3">3</xref>, the probability of cost-effectiveness calculated using the p-value was nearly identical to that calculated using the bootstrapping method. This finding may be related to the fact that the cost data in this trial did not vary by patient within treatment group. All patients receiving a loop recorder had costs of $648.50 and all patients receiving a Holter monitor had costs of $212.92. When both patient level costs and effect data vary, net benefit regression can still be used to construct a CEAC (i.e., the statistical uncertainty involving the cost and effect data is expressed in the p-value). However, the assumptions necessary to use the p-value may not hold; for example, the presence of skewness or heteroskedasticity in the data suggests caution when using the p-value. Indeed, for low values of &#x003bb;, the almost inevitable non-normal distribution of costs can challenge the assumptions made in using the p-value in the regression approach. For this reason, empirical examples of the NBRF typically use bootstrapping to generate CEACs [<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. However, as noted by a reviewer, the bootstrap is not necessarily robust, particularly in CEAs when there is also concern about the use of parametric methods because of skewness. In addition to the incremental net benefit (&#x003b2;<sub>1</sub>), net benefit regression provides an estimate of the mean net benefit of "usual care" (&#x003b2;<sub>0</sub>), the mean net benefit of "new treatment" (&#x003b2;<sub>0 </sub>+ &#x003b2;<sub>1</sub>) and also regression diagnostic information (e.g., the residual errors and R<sup>2</sup>). Thus, the NBRF facilitates using regression diagnostics (see the "Regression Diagnostics" section and Figure 6 in [<xref ref-type="bibr" rid="B22">22</xref>]) to improve the quality of economic evaluations.</p></sec><sec><title>Conclusion</title><p>The NBRF provides a way for economic evaluations to use the variety of tools that have been developed for regression. For any value of &#x003bb;, net benefit regression produces a cost-effectiveness estimate, and the CEAC produces a cost-effectiveness probability. To allow for the fact that the analyst does not know the decision maker's &#x003bb;, the horizontal axis of a CEAC varies in the style of a sensitivity analysis, and the statistical uncertainty about cost-effectiveness is reflected on the vertical axis. This paper has illustrated how the NBRF can be used to construct a CEAC. When the link from a net benefit regression's p-value to the probability of cost-effectiveness is tentative, bootstrapping provides an alternative.</p></sec><sec><title>Abbreviations</title><p>CEACs: cost-effectiveness acceptability curves</p><p>ICER: incrememtnal cost-effectiveness ratio</p><p>NBRF: net benefit regression framework</p><p>OHIP: Ontario Health Insurance Plan</p><p>OLS: ordinary least squares</p><p>QALY: quality adjusted life year</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JSH- 1) made substantial contributions to conception and design, analysis and interpretation of data; 2) was involved in drafting the manuscript and revising the manuscript critically for important intellectual content; and 3) has given final approval of the version to be published.</p><p>MAR- 1) made substantial contributions to the conception and design, analysis and interpretation of data; 2) was involved in revising the manuscript critically for important intellectual content; and 3) has given final approval of the version to be published.</p><p>ADK- 1) made substantial contributions to conception and design, analysis and interpretation of data; 2) was involved in revising the manuscript critically for important intellectual content; and 3) has given final approval of the version to be published.</p><p>The first Figure in <italic>bmcFIGS9.doc </italic>is Figure <xref ref-type="fig" rid="F1">1</xref> (it is formatted to fit portrait). The second figure in <italic>bmcFIGS9.doc </italic>is Figure <xref ref-type="fig" rid="F2">2</xref> (it is formatted to fit landscape).</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6963/6/68/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to thank George J. Klein, Raymond Yee, Allan C. Skanes and Lorne J. Gula for their assistance with the initial patient study. Dr. Hoch gratefully acknowledges funding from a Career Scientist Award from the Ontario Ministry of Health and Long Term Care. The Centre for Research on Inner City Health is sponsored by the Ontario Ministry of Health and Long-Term Care. The opinions, results, and conclusions are those of the authors and no endorsement by the ministry is intended or should be inferred.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>I</given-names></name><name><surname>Dimant</surname><given-names>J</given-names></name></person-group><article-title>Importance of Holter monitoring in patients with periodic cerebral symptoms</article-title><source>Ann Neurol</source><year>1977</year><volume>1</volume><fpage>470</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">363045</pub-id><pub-id pub-id-type="doi">10.1002/ana.410010511</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Linzer</surname><given-names>M</given-names></name><name><surname>Gabelman</surname><given-names>M</given-names></name><name><surname>Smoller</surname><given-names>S</given-names></name><name><surname>Scheuer</surname><given-names>J</given-names></name></person-group><article-title>Syncope in a general hospital patient population. Usefulness of the radionuclide brain scan, electroencephalogram, and 24-hour Holter monitor</article-title><source>N Y State J Med</source><year>1983</year><volume>83</volume><fpage>1161</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">6580561</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bass</surname><given-names>EB</given-names></name><name><surname>Curtiss</surname><given-names>EI</given-names></name><name><surname>Arena</surname><given-names>VC</given-names></name><name><surname>Hanusa</surname><given-names>BH</given-names></name><name><surname>Cecchetti</surname><given-names>A</given-names></name><name><surname>Karpf</surname><given-names>M</given-names></name><name><surname>Kapoor</surname><given-names>WN</given-names></name></person-group><article-title>The duration of Holter monitoring in patients with syncope. Is 24 hours enough?</article-title><source>Arch Intern Med</source><year>1990</year><volume>150</volume><fpage>1073</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">2331188</pub-id><pub-id pub-id-type="doi">10.1001/archinte.150.5.1073</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linzer</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>EH</given-names></name><name><surname>Estes</surname><given-names>NAIII</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Vorperian</surname><given-names>VR</given-names></name><name><surname>Kapoor</surname><given-names>WN</given-names></name></person-group><article-title>Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians</article-title><source>Ann Intern Med</source><year>1997</year><volume>126</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">9182479</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivakumaran</surname><given-names>S</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Klein</surname><given-names>GJ</given-names></name><name><surname>Finan</surname><given-names>J</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Renner</surname><given-names>S</given-names></name><name><surname>Skanes</surname><given-names>AC</given-names></name></person-group><article-title>A prospective randomized comparison of loop recorders versus Holter monitors in patients with syncope or presyncope</article-title><source>Am J Med</source><year>2003</year><volume>115</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12867227</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(03)00233-X</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>WN</given-names></name></person-group><article-title>Evaluation and management of the patient with syncope</article-title><source>JAMA</source><year>1992</year><volume>268</volume><fpage>2553</fpage><lpage>2560</lpage><pub-id pub-id-type="pmid">1404823</pub-id><pub-id pub-id-type="doi">10.1001/jama.268.18.2553</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>TC</given-names></name><name><surname>Heitzman</surname><given-names>MR</given-names></name></person-group><article-title>Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope</article-title><source>Am J Cardiol</source><year>1984</year><volume>53</volume><fpage>1013</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">6702676</pub-id><pub-id pub-id-type="doi">10.1016/0002-9149(84)90628-3</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linzer</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>EH</given-names></name><name><surname>Estes</surname><given-names>NAIII</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Vorperian</surname><given-names>VR</given-names></name><name><surname>Kapoor</surname><given-names>WN</given-names></name></person-group><article-title>Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians</article-title><source>Ann Intern Med</source><year>1997</year><volume>127</volume><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">9214258</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimetbaum</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Ho</surname><given-names>KK</given-names></name><name><surname>Zebede</surname><given-names>J</given-names></name><name><surname>Josephson</surname><given-names>ME</given-names></name><name><surname>Goldberger</surname><given-names>AL</given-names></name></person-group><article-title>Utility of patient-activated cardiac event recorders in general clinical practice</article-title><source>Am J Cardiol</source><year>1997</year><volume>79</volume><fpage>371</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">9036763</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(96)00766-7</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimetbaum</surname><given-names>PJ</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Josephson</surname><given-names>ME</given-names></name><name><surname>Goldberger</surname><given-names>AL</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name></person-group><article-title>Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations. A cost-effectiveness analysis</article-title><source>Ann Intern Med</source><year>1998</year><volume>128</volume><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">9634426</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuchert</surname><given-names>A</given-names></name><name><surname>Maas</surname><given-names>R</given-names></name><name><surname>Kretzschmar</surname><given-names>C</given-names></name><name><surname>Behrens</surname><given-names>G</given-names></name><name><surname>Kratzmann</surname><given-names>I</given-names></name><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group><article-title>Diagnostic yield of external electrocardiographic loop recorders in patients with recurrent syncope and negative tilt table test</article-title><source>Pacing Clin Electrophysiol</source><year>2003</year><volume>26</volume><fpage>1837</fpage><lpage>1840</lpage><pub-id pub-id-type="pmid">12930497</pub-id><pub-id pub-id-type="doi">10.1046/j.1460-9592.2003.t01-1-00277.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>WN</given-names></name><name><surname>Cha</surname><given-names>R</given-names></name><name><surname>Peterson</surname><given-names>JR</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>Karpf</surname><given-names>M</given-names></name></person-group><article-title>Prolonged electrocardiographic monitoring in patients with syncope. Importance of frequent or repetitive ventricular ectopy</article-title><source>Am J Med</source><year>1987</year><volume>82</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">2432783</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(87)90372-X</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>WN</given-names></name><name><surname>Karpf</surname><given-names>M</given-names></name><name><surname>Maher</surname><given-names>Y</given-names></name><name><surname>Miller</surname><given-names>RA</given-names></name><name><surname>Levey</surname><given-names>GS</given-names></name></person-group><article-title>Syncope of unknown origin. The need for a more cost-effective approach to its diagnosis evaluation</article-title><source>JAMA</source><year>1982</year><volume>247</volume><fpage>2687</fpage><lpage>2691</lpage><pub-id pub-id-type="pmid">6804646</pub-id><pub-id pub-id-type="doi">10.1001/jama.247.19.2687</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>el-Atassi</surname><given-names>R</given-names></name><name><surname>Kalbfleisch</surname><given-names>S</given-names></name><name><surname>Langberg</surname><given-names>JJ</given-names></name><name><surname>Morady</surname><given-names>F</given-names></name></person-group><article-title>The economic burden of unrecognized vasodepressor syncope</article-title><source>Am J Med</source><year>1993</year><volume>95</volume><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">8238063</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(93)90329-N</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fogel</surname><given-names>RI</given-names></name><name><surname>Evans</surname><given-names>JJ</given-names></name><name><surname>Prystowsky</surname><given-names>EN</given-names></name></person-group><article-title>Utility and cost of event recorders in the diagnosis of palpitations, presyncope, and syncope</article-title><source>Am J Cardiol</source><year>1997</year><volume>79</volume><fpage>207</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">9193028</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(96)00717-5</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Klein</surname><given-names>GJ</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Manda</surname><given-names>V</given-names></name></person-group><article-title>The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope</article-title><source>Am Heart J</source><year>1999</year><volume>137</volume><fpage>870</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">10220636</pub-id><pub-id pub-id-type="doi">10.1016/S0002-8703(99)70411-4</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>CS</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Klein</surname><given-names>GJ</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Skanes</surname><given-names>AC</given-names></name><name><surname>Manda</surname><given-names>V</given-names></name><name><surname>Norris</surname><given-names>C</given-names></name></person-group><article-title>A cost effective approach to the investigation of syncope: relative merit of different diagnostic strategies</article-title><source>Can J Cardiol</source><year>1999</year><volume>15</volume><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">10350668</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nyman</surname><given-names>JA</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Bland</surname><given-names>PC</given-names></name><name><surname>Griffiths</surname><given-names>S</given-names></name><name><surname>Manda</surname><given-names>V</given-names></name></person-group><article-title>The costs of recurrent syncope of unknown origin in elderly patients</article-title><source>Pacing Clin Electrophysiol</source><year>1999</year><volume>22</volume><fpage>1386</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">10527021</pub-id><pub-id pub-id-type="doi">10.1111/j.1540-8159.1999.tb00633.x</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Klein</surname><given-names>GJ</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Hoch</surname><given-names>JS</given-names></name><name><surname>Skanes</surname><given-names>AC</given-names></name></person-group><article-title>Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>42</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12906979</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00659-4</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rockx</surname><given-names>MA</given-names></name><name><surname>Hoch</surname><given-names>JS</given-names></name><name><surname>Klein</surname><given-names>GJ</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Skanes</surname><given-names>AC</given-names></name><name><surname>Gula</surname><given-names>LJ</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name></person-group><article-title>Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><fpage>1065</fpage><pub-id pub-id-type="pmid">16290999</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2005.08.003</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>E</given-names></name><name><surname>Marshall</surname><given-names>DA</given-names></name><name><surname>Levy</surname><given-names>AR</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name></person-group><article-title>Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation</article-title><source>BMC Health Serv Res</source><year>2006</year><volume>6</volume><fpage>52</fpage><pub-id pub-id-type="pmid">16623946</pub-id><pub-id pub-id-type="doi">10.1186/1472-6963-6-52</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>JS</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Willan</surname><given-names>AR</given-names></name></person-group><article-title>Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis</article-title><source>Health Econ</source><year>2002</year><volume>11</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">12112491</pub-id><pub-id pub-id-type="doi">10.1002/hec.678</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Hout</surname><given-names>BA</given-names></name><name><surname>Al</surname><given-names>MJ</given-names></name><name><surname>Gordon</surname><given-names>GS</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name></person-group><article-title>Costs, effects and C/E-ratios alongside a clinical trial</article-title><source>Health Econ</source><year>1994</year><volume>3</volume><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">7827647</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>A</given-names></name><name><surname>Fenn</surname><given-names>P</given-names></name></person-group><article-title>Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane</article-title><source>Health Econ</source><year>1998</year><volume>7</volume><fpage>723</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">9890333</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1099-1050(199812)7:8&#x0003c;723::AID-HEC392&#x0003e;3.0.CO;2-O</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lothgren</surname><given-names>M</given-names></name><name><surname>Zethraeus</surname><given-names>N</given-names></name></person-group><article-title>Definition, interpretation and calculation of cost-effectiveness acceptability curves</article-title><source>Health Econ</source><year>2000</year><volume>9</volume><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">11103928</pub-id><pub-id pub-id-type="doi">10.1002/1099-1050(200010)9:7&#x0003c;623::AID-HEC539&#x0003e;3.0.CO;2-V</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>E</given-names></name><name><surname>Claxton</surname><given-names>K</given-names></name><name><surname>Sculpher</surname><given-names>M</given-names></name></person-group><article-title>Representing uncertainty: the role of cost-effectiveness acceptability curves</article-title><source>Health Econ</source><year>2001</year><volume>10</volume><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">11747057</pub-id><pub-id pub-id-type="doi">10.1002/hec.635</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>E</given-names></name><name><surname>O'Brien</surname><given-names>BJ</given-names></name><name><surname>Briggs</surname><given-names>A</given-names></name></person-group><article-title>Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions</article-title><source>Health Econ</source><year>2004</year><volume>13</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">15127421</pub-id><pub-id pub-id-type="doi">10.1002/hec.903</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Hagan</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>JW</given-names></name><name><surname>Montmartin</surname><given-names>J</given-names></name></person-group><article-title>Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio</article-title><source>Pharmacoeconomics</source><year>2000</year><volume>17</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">10947489</pub-id><pub-id pub-id-type="doi">10.2165/00019053-200017040-00004</pub-id></citation></ref><ref id="B29"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Myles</surname><given-names>JP</given-names></name></person-group><source>Bayesian approaches to clinical trials and health-care evaluation</source><series>Statistics in practice (Chichester, England)</series><year>2004</year><publisher-name>Chichester, John Wiley &#x00026; Sons</publisher-name></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>SN</given-names></name></person-group><article-title>Introduction to Bayesian methods I: measuring the strength of evidence</article-title><source>Clin Trials</source><year>2005</year><volume>2</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">16281426</pub-id><pub-id pub-id-type="doi">10.1191/1740774505cn098oa</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Hagan</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>JW</given-names></name></person-group><article-title>A framework for cost-effectiveness analysis from clinical trial data</article-title><source>Health Econ</source><year>2001</year><volume>10</volume><fpage>303</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">11400253</pub-id><pub-id pub-id-type="doi">10.1002/hec.617</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>JW</given-names></name><name><surname>O'Hagan</surname><given-names>A</given-names></name></person-group><article-title>Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data</article-title><source>Int J Technol Assess Health Care</source><year>2002</year><volume>18</volume><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">12602079</pub-id><pub-id pub-id-type="doi">10.1017/S0266462302000594</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al</surname><given-names>MJ</given-names></name><name><surname>van Hout</surname><given-names>BA</given-names></name></person-group><article-title>A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty</article-title><source>Health Econ</source><year>2000</year><volume>9</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">11103926</pub-id><pub-id pub-id-type="doi">10.1002/1099-1050(200010)9:7&#x0003c;599::AID-HEC530&#x0003e;3.0.CO;2-#</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stinnett</surname><given-names>AA</given-names></name><name><surname>Mullahy</surname><given-names>J</given-names></name></person-group><article-title>Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis</article-title><source>Med Decis Making</source><year>1998</year><volume>18</volume><fpage>S68</fpage><lpage>S80</lpage><pub-id pub-id-type="pmid">9566468</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tambour</surname><given-names>M</given-names></name><name><surname>Zethraeus</surname><given-names>N</given-names></name><name><surname>Johannesson</surname><given-names>M</given-names></name></person-group><article-title>A note on confidence intervals in cost-effectiveness analysis</article-title><source>Int J Technol Assess Health Care</source><year>1998</year><volume>14</volume><fpage>467</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">9780533</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCrone</surname><given-names>P</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Proudfoot</surname><given-names>J</given-names></name><name><surname>Ryden</surname><given-names>C</given-names></name><name><surname>Cavanagh</surname><given-names>K</given-names></name><name><surname>Shapiro</surname><given-names>DA</given-names></name><name><surname>Ilson</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>JA</given-names></name><name><surname>Goldberg</surname><given-names>D</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>I</given-names></name><name><surname>Everitt</surname><given-names>B</given-names></name><name><surname>Tylee</surname><given-names>A</given-names></name></person-group><article-title>Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial</article-title><source>Br J Psychiatry</source><year>2004</year><volume>185</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15231556</pub-id><pub-id pub-id-type="doi">10.1192/bjp.185.1.55</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>DH</given-names></name><name><surname>McCrone</surname><given-names>P</given-names></name><name><surname>Wright</surname><given-names>K</given-names></name><name><surname>Kerr</surname><given-names>N</given-names></name></person-group><article-title>Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study</article-title><source>Br J Psychiatry</source><year>2005</year><volume>186</volume><fpage>500</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">15928361</pub-id><pub-id pub-id-type="doi">10.1192/bjp.186.6.500</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>EM</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Jackson</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Lamy</surname><given-names>A</given-names></name><name><surname>Culler</surname><given-names>S</given-names></name><name><surname>Caro</surname><given-names>J</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name></person-group><article-title>Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation</article-title><source>Am Heart J</source><year>2006</year><volume>151</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16368322</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.044</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Illustrating the relationship between the p-value for the "new treatment" indicator variable in a net benefit regression (i.e., b<sub>1</sub>the incremental net benefit) and the probability that a new treatment is cost-effective</p></caption><graphic xlink:href="1472-6963-6-68-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Cost-effectiveness acceptability curve (CEAC) showing the probability that loop recorders are cost-effective compared to Holter monitors over a range of values for willingness to pay for an additional syncope diagnosis.</p></caption><graphic xlink:href="1472-6963-6-68-2"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Construction of the dependent variable (net benefit) when &#x003bb; = $1000</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Net Benefit with &#x003bb; = $1000</td><td align="center">Number of Subjects</td><td align="center">Treatment Group</td><td align="center">Successful outcome</td></tr></thead><tbody><tr><td align="left">$1000 * 1 - $648.50 = $351.50</td><td align="center">31</td><td align="center">Loop recorder</td><td align="center">Yes</td></tr><tr><td align="left">$1000 * 0 - $648.50 = - $648.50</td><td align="center">18</td><td align="center">Loop recorder</td><td align="center">No</td></tr><tr><td align="left">$1000 * 1 - $212.92 = $787.08</td><td align="center">12</td><td align="center">Holter monitor</td><td align="center">Yes</td></tr><tr><td align="left">$1000 * 0 - $212.92 = - $212.92</td><td align="center">39</td><td align="center">Holter monitor</td><td align="center">No</td></tr></tbody></table><table-wrap-foot><p>NOTE: All loop recorders cost $648.50 and all Holter monitors cost $212.92.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Simple net benefit regression estimates (N = 100)<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Explanatory variables</td><td align="left">&#x003bb; = $500<sup>b </sup>coefficient (p-value)</td><td align="left">&#x003bb; = $1000 coefficient (p-value)</td><td align="left">&#x003bb; = $1500 coefficient (p-value)</td><td align="left">&#x003bb; = $2000 coefficient (p-value)</td><td align="left">&#x003bb; = $2500 coefficient (p-value)</td></tr></thead><tbody><tr><td align="center">Constant term</td><td align="center">-95.27 (0.004)</td><td align="center">22.37 (0.728)</td><td align="center">140.02 (0.149)</td><td align="center">257.67 (0.047)</td><td align="center">375.32 (0.021)</td></tr><tr><td align="center"><italic>LOOP</italic></td><td align="center">-236.90 (&#x0003c;0.001)</td><td align="center">-38.22 (0.678)</td><td align="center">160.46 (0.246)</td><td align="center">359.14 (0.053)</td><td align="center">557.82 (0.017)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center">R-squared</td><td align="center">0.2143</td><td align="center">0.0018</td><td align="center">0.0137</td><td align="center">0.0377</td><td align="center">0.0570</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>The treatment indicator variable <italic>LOOP </italic>= 1 for the Loop recorder and 0 for the Holter monitor.</p><p><sup>b </sup>All monetary figures are in US dollars.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Using the net benefit regression results to create a cost-effectiveness acceptability curve (CEAC) with a comparison to bootstrapping the probability of cost-effectiveness</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">&#x003bb;</td><td align="center" colspan="2">Treatment Indicator Coefficient</td><td align="center">One sided p-value</td><td align="center">Probability of cost-effectiveness (regression)</td><td align="center">Probability of cost-effectiveness (bootstrapping)</td></tr><tr><td></td><td colspan="2"><hr></hr></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">Estimate</td><td align="center">p-value</td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="center">$500</td><td align="center">-236.90</td><td align="center">&#x0003c;0.001</td><td align="center">&#x02248; 0.000</td><td align="center">0%</td><td align="center">0%</td></tr><tr><td align="center">$750</td><td align="center">-137.56</td><td align="center">0.048</td><td align="center">0.024</td><td align="center">2%</td><td align="center">2%</td></tr><tr><td align="center">$1000</td><td align="center">-38.22</td><td align="center">0.678</td><td align="center">0.339</td><td align="center">34%</td><td align="center">33%</td></tr><tr><td align="center">$1250</td><td align="center">61.12</td><td align="center">0.595</td><td align="center">0.298</td><td align="center">70%</td><td align="center">71%</td></tr><tr><td align="center">$1500</td><td align="center">160.46</td><td align="center">0.246</td><td align="center">0.123</td><td align="center">88%</td><td align="center">89%</td></tr><tr><td align="center">$1750</td><td align="center">259.80</td><td align="center">0.108</td><td align="center">0.054</td><td align="center">95%</td><td align="center">94%</td></tr><tr><td align="center">$2000</td><td align="center">359.14</td><td align="center">0.053</td><td align="center">0.027</td><td align="center">97%</td><td align="center">97%</td></tr><tr><td align="center">$2250</td><td align="center">458.48</td><td align="center">0.028</td><td align="center">0.014</td><td align="center">99%</td><td align="center">98%</td></tr><tr><td align="center">$2500</td><td align="center">557.82</td><td align="center">0.017</td><td align="center">0.009</td><td align="center">99%</td><td align="center">99%</td></tr><tr><td align="center">$2750</td><td align="center">657.16</td><td align="center">0.011</td><td align="center">0.006</td><td align="center">99%</td><td align="center">99%</td></tr><tr><td align="center">$3000</td><td align="center">756.50</td><td align="center">0.007</td><td align="center">0.004</td><td align="center">100%</td><td align="center">100%</td></tr></tbody></table></table-wrap></sec></back></article>


